Canada markets closed

23andMe Holding Co. (ME)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.4604-0.0225 (-4.66%)
At close: 04:00PM EDT
0.4611 +0.00 (+0.15%)
After hours: 07:56PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.4829
Bid0.4585 x 1000
Ask0.4654 x 700
Day's Range0.4525 - 0.5092
52 Week Range0.3500 - 2.2100
Avg. Volume7,690,580
Market Cap222.335M
Beta (5Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-1.1100
Earnings DateMay 26, 2024 - May 30, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.23

    23andMe CEO Anne Wojcicki Says She’s Weighing Buyout Bid

    In what looks like a potentially downbeat ending to 23andMe journey as a public company, founder and CEO Anne Wojcicki has offered to take the DNA testing business private. Wojcicki, who controls more than 20% of 23andMe’s stock, with about 49% voting control, told the company that she is considering making an offer to buy the shares she doesn’t already own. Neither Wojcicki nor the company have commented on what she might be willing to pay, but investors appear skeptical that it will come at a premium price.

  • Bloomberg

    23andMe Jumps as CEO Floats Taking DNA Tester Private

    (Bloomberg) -- DNA testing firm 23andMe Holding Co.’s shares soared after Chief Executive Officer Anne Wojcicki said she’s considering taking the struggling company private, less than three years after it began selling shares.Most Read from BloombergDubai Grinds to Standstill as Flooding Hits CityElon Wants His Money BackSingapore Loses ‘World’s Best Airport’ Crown to QatarRecord Rainfall in Dubai? Blame Climate Change, Not Cloud SeedingRed Lobster Considers Bankruptcy to Deal With Leases and La

  • GlobeNewswire

    23andMe announces CEO’s intention to pursue a potential take-private

    SOUTH SAN FRANCISCO, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has been made aware that Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, is considering making a proposal to acquire all of the outstanding shares of 23andMe that she does not currently own, as she stated in an amendment dated April 17, 2024 to her Schedule 13D filing with the Securities and E